Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT06052839RecruitingPhase 2
Pulsed chemo plus pembrolizumab for head and neck cancer
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06048250RecruitingPhase 1
Mezigdomide after Abecma for multiple myeloma
This trial tests a new drug called mezigdomide (CC-92480) for people with multiple myeloma who have already received the CAR T-cell therapy Abecma. The goal is to see if mezigdomide can help keep the cancer under control after Abecma.
Duarte, CaliforniaAges 18 years+ - NCT06050694RecruitingPhase 2
Testing glofitamab plus chemo for untreated DLBCL
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Toronto, OntarioAges 18 years+ - NCT06047977RecruitingPhase 1
Immune cell therapy for high-risk solid tumors in children and young adults
This trial uses a patient's own tumor-fighting immune cells (TILs) to treat high-risk solid tumors outside the brain in children and young adults. It has two parts: first, a tumor sample is collected during surgery, and then the immune cells are grown in a lab and given back to the patient to attack the cancer.
St. Petersburg, FloridaAges 1–21 - NCT06046833Recruiting
Continuous glucose monitoring for diabetic gastroparesis
This study tests whether a continuous glucose monitor (CGM) can help manage blood sugar in people with diabetes and gastroparesis (slow stomach emptying). If you have type 1 or type 2 diabetes and stomach symptoms, this could help doctors better understand your glucose patterns.
Cleveland, OhioAges 18 years+ - NCT06037187Recruiting
Blood clotting study for immune skin diseases
This study looks at how immune-related skin diseases like bullous pemphigoid and lupus affect blood clotting. The results could help doctors better understand and manage clotting risks in these patients.
Omaha, NebraskaAges 19 years+ - NCT04510766Recruiting
Test tumor genetic results to guide early trial treatments
This trial looks at your tumor’s genetic information from stored tissue to help match you to early-phase treatment options. It may help doctors find a therapy that fits your tumor, especially when standard options have limited benefit.
BellinzonaAges 18 years+ - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT06005870RecruitingPhase 2
Zanubrutinib with R-CHOP for newly diagnosed p53-positive DLBCL
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06029309RecruitingPhase 1/Phase 2
Zanubrutinib and tafasitamab for mantle cell lymphoma
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Miami, FloridaAges 18 years+ - NCT06026319RecruitingPhase 1
Immune cells for lymphoma that has returned
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
Boston, MassachusettsAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06018766RecruitingPhase 2
LAM-001 for lung transplant patients with BOS
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
San Francisco, CaliforniaAges 18 years+ - NCT06008691Recruiting
Study of newer antibodies for B-cell lymphoma in Italy
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
Viagrande, CataniaAges 18 years+ - NCT06019975Recruiting
Using Brain PET Scans to Diagnose Autoimmune Encephalitis
This study uses a special brain scan (FDG-PET) to better understand autoimmune encephalitis, a condition where the immune system attacks the brain. It may help doctors improve diagnosis by comparing PET scan results with other tests you already had.
Udine, Friuli Venezia GiuliaAges Any age - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06004349Recruiting
Genetic study of autoinflammatory diseases
This study looks for genes linked to autoinflammatory diseases like VEXAS syndrome. You or your family member can join by mailing in a blood or saliva sample to help researchers better understand these conditions.
New York, New YorkAges 1 month+ - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT06013579Recruiting
Exercise study for older adults with HIV
This study tests whether high-intensity exercise can help improve thinking and memory, and build lasting exercise habits, in older adults living with HIV who feel tired and are not very active.
Birmingham, AlabamaAges 50–80 - NCT06015542RecruitingPhase 2
Giving Elranatamab at Home for Relapsed Multiple Myeloma
This study tests if people with relapsed multiple myeloma can safely give themselves a medicine called elranatamab at home. It aims to make treatment more convenient while still being safe and effective.
OdenseAges 18 years+ - NCT06004011Recruiting
Cancer workforce roles for people living with HIV
This study looks at a program to help people living with HIV take on cancer-fighting roles (like caregiving or support workers). It follows volunteers for 3 years and checks how well the program works for them and their community.
LusakaAges 15–39 - NCT06023589RecruitingPhase 3
Testing tezepelumab for kids with severe asthma
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
Montgomery, AlabamaAges 5–11
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.